Combination of anti- PD1 or anti- CTLA-4 checkpoint immunotherapy with CSF-1/CSF-1R blockade improved anti-tumour immunity and led to the regression of even established primary pancreatic tumours [103]. Here, CSF1R is linked to neoplasm.